Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 127.42M | 221.90M | 9.30M | 77.65M | 69.72M | 8.25M |
Gross Profit | 123.53M | 218.02M | 6.86M | 74.21M | 66.60M | 5.16M |
EBITDA | -551.92M | -436.83M | -565.47M | -397.44M | -533.83M | -465.75M |
Net Income | -667.97M | -535.76M | -643.20M | -493.96M | -639.30M | -483.93M |
Balance Sheet | ||||||
Total Assets | 881.64M | 919.34M | 546.38M | 623.04M | 1.01B | 703.59M |
Cash, Cash Equivalents and Short-Term Investments | 540.60M | 681.10M | 434.88M | 428.27M | 787.51M | 607.09M |
Total Debt | 10.12M | 1.73B | 1.74B | 1.72B | 1.73B | 495.79M |
Total Liabilities | 2.52B | 2.38B | 1.89B | 1.87B | 1.88B | 595.70M |
Stockholders Equity | -1.64B | -1.46B | -1.35B | -1.25B | -870.41M | 57.91M |
Cash Flow | ||||||
Free Cash Flow | -507.84M | -521.66M | -529.03M | -425.81M | -546.18M | -407.23M |
Operating Cash Flow | -500.42M | -520.73M | -527.72M | -419.49M | -497.93M | -399.71M |
Investing Cash Flow | 36.43M | 60.78M | 54.03M | 453.15M | -200.83M | -52.99M |
Financing Cash Flow | 529.24M | 748.46M | 451.54M | -13.13M | 736.45M | 447.19M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
64 Neutral | $5.76B | 148.73 | 19.70% | ― | 33.54% | -6.13% | |
60 Neutral | $8.12B | ― | 35.68% | ― | -41.71% | -9.37% | |
56 Neutral | $6.61B | ― | -20.00% | ― | 112.46% | 54.33% | |
55 Neutral | €4.87B | 18.24 | -49.50% | 1.94% | 13.92% | -4.82% | |
53 Neutral | $1.79B | 19.61 | -23.61% | ― | 59.15% | -1881.09% | |
52 Neutral | $6.93B | ― | -36.68% | ― | -100.00% | 5.49% | |
50 Neutral | $8.29B | ― | -47.71% | ― | 99.19% | 48.43% |
On June 27, 2025, BridgeBio Pharma, Inc. and its subsidiary Eidos Therapeutics, Inc. entered into a Royalty Interest Purchase and Sale Agreement with Acoramidis Royalty SPV, LP and LSI Financing Fund, LP. Eidos sold certain royalty rights on net sales of products containing acoramidis in the EU to the purchasers for $300 million. This agreement provides BridgeBio with immediate capital while capping the purchasers’ royalty rights and offering security interests in specific assets, potentially impacting the company’s financial strategy and stakeholder interests.
The most recent analyst rating on (BBIO) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.
BridgeBio Pharma held its Annual Meeting on June 20, 2025, where stockholders voted on several key proposals. These included the election of five Class III directors, approval of executive compensation, ratification of Deloitte & Touche LLP as the independent accounting firm, and amendments to the company’s stock option plan and certificate of incorporation. The meeting also approved the adjournment of the meeting if necessary due to insufficient votes.
The most recent analyst rating on (BBIO) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.